Erratum to: Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis

Sirkku Pollari · Sanna-Maria Käkönen · Henrik Edgren ·
Maija Wolf · Pekka Kohonen · Henri Sara ·
Theresa Guise · Matthias Nees · Olli Kallioniemi

Published online: 13 July 2011
© Springer Science+Business Media, LLC. 2011

Erratum to: Breast Cancer Res Treat DOI 10.1007/s10549-010-0848-5

The authors would like to inform that the description for the data sets used in the Kaplan–Meier analysis of relapse-free survival and the number of samples used in the Kaplan–Meier analysis of overall survival were incorrectly reported in the original publication. PSAT1 expression was analyzed in almost twice as many samples as reported. The results and significance of all the analyses remain unchanged. It should read as follows:

The online version of the original article can be found under doi:
[10.1007/s10549-010-0848-5](https://doi.org/10.1007/s10549-010-0848-5).

S. Pollari (✉) · P. Kohonen · H. Sara · M. Nees
Medical Biotechnology, VTT Technical Research Center
of Finland and Turku Center for Biotechnology,
Turku, Finland
e-mail: ext-sirkku.pollari@vtt.fi

S.-M. Käkönen
Institute of Biomedicine, Department of Anatomy,
University of Turku, Turku, Finland

H. Edgren · M. Wolf · O. Kallioniemi
Institute for Molecular Medicine Finland (FIMM),
University of Helsinki, Helsinki, Finland

T. Guise
Division of Endocrinology, Indiana University,
Indianapolis, IN, USA

Present Address:
S.-M. Käkönen
Amgen AB Finland, Espoo, Finland

Materials and methods

Association of PHGDH, PSAT1, PSPH, and SLC1A4 expression with time to relapse in the Affymetrix gene expression studies GSE6532, GSE12276, and **GSE9195 (samples analyzed with U133 Plus 2.0 Array, $n = 368$)** and with overall survival in the Affymetrix gene expression studies GSE3494 and GSE1456 (**$n = 382$ for PHGDH, PSPH, SLC1A4; $n = 764$ for PSAT1**) was assessed by Kaplan–Meier analysis.

Results

First, we analyzed the correlation of PHGDH, PSAT1, PSPH, and SLC1A4 expression to time to relapse in 368 breast cancers and to overall survival time in **382 (PHGDH, PSPH, SLC1A4) or 764 breast cancers (PSAT1)**.

The Fig. 6b with the corrected sample numbers is given below.